Docoh
Loading...

CGTX Cognition Therapeutics

News

From Benzinga Pro
48 Biggest Movers From Yesterday
12 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT performance drink in Walmart stores across Florida metropolitan areas.
12 Health Care Stocks Moving In Tuesday's Intraday Session
11 Jan 22
Intraday Update, Markets, Movers
30 Stocks Moving In Tuesday's Mid-Day Session
11 Jan 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
11 Jan 22
Pre-Market Outlook, Markets, Movers
Cognition Therapeutics US Patent & Trademark Office Shows Abstract For Co.'s 'Compositions for treating neurodegenerative diseases'
4 Jan 22
News, Legal
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11214540.PN.&OS=PN/11214540&RS=PN/11214540
12 Health Care Stocks Moving In Wednesday's After-Market Session
29 Dec 21
Movers
Gainers Cognition Therapeutics (NASDAQ:CGTX) shares rose 14.9% to $6.62 during Wednesday's after-market session. The market value of their outstanding shares is at $145.8 million.
Cognition Therapeutics Q3 EPS $(8.12) Down From $(5.31) YoY
18 Nov 21
Earnings, News
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(8.12) per share. This is a 52.92 percent decrease over losses of $(5.31) per share from the same period last year.
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021
3 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Oppenheimer Initiates Coverage On Cognition Therapeutics with Outperform Rating, Announces Price Target of $22
3 Nov 21
News, Price Target, Initiation, Analyst Ratings
Oppenheimer analyst Jay Olson initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Outperform rating and announces Price Target of $22.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.